Skip to content
★ Sign in to follow
陆

陆惠萍

Board Director
Director
泽璟制药
Total declarations
5
Company
1
▲ Purchases (5 ops.)
€175k
▼ Sales (0 ops.)
—

Latest filing published 21 Mar 2022 for 泽璟制药, €52k.

Filing timeline

BuySale
陆惠萍

Insider track record

Disclosed buys
5
Disclosed sells
0
Signal history

Closed purchases

Market purchases
5
Positive at T+90
20%
Median T+90
-1.6%

Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 21 Mar 2022 · 1693 days ago · €52k
    +37.9%
    Entry CN¥36.86 · Close at T+365 CN¥50.82
  • Filed 17 Mar 2022 · 1697 days ago · €5,037
    +33.5%
    Entry CN¥36.31 · Close at T+365 CN¥48.47
  • Filed 16 Mar 2022 · 1698 days ago · €39k
    +30.9%
    Entry CN¥37.58 · Close at T+365 CN¥49.20
  • Filed 15 Mar 2022 · 1699 days ago · €25k
    +46.4%
    Entry CN¥35.10 · Close at T+365 CN¥51.38
  • Filed 10 Mar 2022 · 1704 days ago · €53k
    +32.4%
    Entry CN¥37.75 · Close at T+365 CN¥49.97

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

陆惠萍: trading record in brief

陆惠萍 is a declared insider of 泽璟制药 (board member), with filings sourced from SSE / SZSE (CSRC). We count 5 filings; the first trade dates from 10 March 2022 and the latest from 21 March 2022.

The open-market record is one-sided, with 5 purchases worth €175k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.

A typical purchase (the median) is worth €39k. 5 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 5 purchases with a full 90-day history, the hit rate stands at 20% and the median 90-day move at -1.6%. This is a record of the past, not a forecast.

The newest entry dates from 21 March 2022: an open-market purchase of €52k, in 泽璟制药. The median gap between trade and publication is zero days: most filings appear on the same day. Until a filing is published, the market cannot know about the trade. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to 陆惠萍

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations5 total
  • ▲
    董事,高级管理人员Executives泽璟制药
    369,587 CNY28SSE
    9,900 shares30.0% of flowA股XSHGSSE:173000005376467140
    Canonical exit: 19 Jun 2022 (T+90)
  • ▲
    董事,高级管理人员Executives泽璟制药
    35,320 CNY25SSE
    1,000 shares2.9% of flowA股XSHGSSE:173000005369557100
    Canonical exit: 15 Jun 2022 (T+90)
  • ▲
    董事,高级管理人员Executives泽璟制药
    274,328 CNY27SSE
    8,000 shares22.4% of flowA股XSHGSSE:173000005367280000
    Canonical exit: 14 Jun 2022 (T+90)
  • ▲
    董事,高级管理人员Executives泽璟制药
    177,115 CNY26SSE
    5,000 shares14.5% of flowA股XSHGSSE:173000005365093660
    Canonical exit: 13 Jun 2022 (T+90)
  • ▲
    董事,高级管理人员Executives泽璟制药
    370,130 CNY22SSE
    10,000 shares30.2% of flowA股XSHGSSE:173000005354873700
    Canonical exit: 8 Jun 2022 (T+90)

5 of 5 declarations